Fulcrum therapeutics enrolls first patient in pivotal global phase 3 clinical trial of losmapimod for facioscapulohumeral muscular dystrophy (fshd)

– reach is the first phase 3 trial for this rare, progressive, and debilitating muscular disease – – losmapimod is an oral small molecule that has the potential to be the first therapy to treat fshd,  the second most common form of muscular dystrophy – – u.s. food and drug administration (fda) granted fast track designation in 2021 –
FULC Ratings Summary
FULC Quant Ranking